Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 14/20 | 0.45 |
| ▸ | MTOR | P42345 | 7/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623283 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2PIK3CAPIK3R1MTORPIK3CD | |
| SCHEMBL189813 | 0.84 | PIK3CA (0.49) | SMN1; SMN2PIK3CAPIK3R1MTORPIK3CD | |
| SCHEMBL27900007 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2PIK3CAPIK3R1MTORPIK3CD | |
| SCHEMBL1864522 | 0.80 | PIK3CA (0.56) | SMN1; SMN2PIK3CAPIK3R1MTORPIK3CD | |
| SCHEMBL1864899 | 0.79 | PIK3CA (0.51) | SMN1; SMN2PIK3CAPIK3R1MTORPIK3CD | |
| SCHEMBL4068062 | 0.79 | PIK3CA (0.44) | SMN1; SMN2PIK3CAPIK3R1MTORPIK3CD | |
| SCHEMBL1862204 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2PIK3CAPIK3R1MTORPIK3CD | |
| SCHEMBL2817644 | 0.78 | PIK3CA (0.51) | SMN1; SMN2PIK3CAPIK3R1MTORPIK3CD | |
| SCHEMBL1862202 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2PIK3CAPIK3R1MTORPIK3CD | |
| SCHEMBL190402 | 0.77 | PIK3CA (0.49) | SMN1; SMN2PIK3CAPIK3R1MTORPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20170362251-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9725461-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-8906909-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8461157-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | SMN1; SMN2 4184/4885PIK3CA 57/4885PIK3R1 106/4885 |
| US-20170362251-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | SMN1; SMN2 4184/4885PIK3CA 57/4885PIK3R1 106/4885 |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | SMN1; SMN2 4184/4885PIK3CA 57/4885PIK3R1 106/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | SMN1; SMN2 4184/4885PIK3CA 57/4885PIK3R1 106/4885 |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | SMN1; SMN2 4192/4885PIK3CA 58/4885PIK3R1 106/4885 |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | KRAS, HRAS, KSR2 | SMN1; SMN2 4049/4885PIK3CA 31/4885PIK3R1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.